Prot #GA29144: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Etrolizumab As An Induction And Maintenance Treatment For Patients With Moderately To Severely Active Crohn’s Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date2/17/16 → 5/30/23

Funding

  • Quintiles, Inc. (Prot #GA29144)
  • Genentech, Inc. (Prot #GA29144)